291 related articles for article (PubMed ID: 21769686)
1. Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo.
Zachar Z; Marecek J; Maturo C; Gupta S; Stuart SD; Howell K; Schauble A; Lem J; Piramzadian A; Karnik S; Lee K; Rodriguez R; Shorr R; Bingham PM
J Mol Med (Berl); 2011 Nov; 89(11):1137-48. PubMed ID: 21769686
[TBL] [Abstract][Full Text] [Related]
2. The disulfide compound α-lipoic acid and its derivatives: A novel class of anticancer agents targeting mitochondria.
Dörsam B; Fahrer J
Cancer Lett; 2016 Feb; 371(1):12-9. PubMed ID: 26604131
[TBL] [Abstract][Full Text] [Related]
3. Targeting pyruvate dehydrogenase kinase signaling in the development of effective cancer therapy.
Anwar S; Shamsi A; Mohammad T; Islam A; Hassan MI
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188568. PubMed ID: 34023419
[TBL] [Abstract][Full Text] [Related]
4. CPI-613 rewires lipid metabolism to enhance pancreatic cancer apoptosis via the AMPK-ACC signaling.
Gao L; Xu Z; Huang Z; Tang Y; Yang D; Huang J; He L; Liu M; Chen Z; Teng Y
J Exp Clin Cancer Res; 2020 Apr; 39(1):73. PubMed ID: 32345326
[TBL] [Abstract][Full Text] [Related]
5. Identification of PDHX as a metabolic target for esophageal squamous cell carcinoma.
Inoue J; Kishikawa M; Tsuda H; Nakajima Y; Asakage T; Inazawa J
Cancer Sci; 2021 Jul; 112(7):2792-2802. PubMed ID: 33964039
[TBL] [Abstract][Full Text] [Related]
6. Lipoic acid and lipoic acid analogs in cancer metabolism and chemotherapy.
Bingham PM; Stuart SD; Zachar Z
Expert Rev Clin Pharmacol; 2014 Nov; 7(6):837-46. PubMed ID: 25284345
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies.
Pardee TS; Lee K; Luddy J; Maturo C; Rodriguez R; Isom S; Miller LD; Stadelman KM; Levitan D; Hurd D; Ellis LR; Harrelson R; Manuel M; Dralle S; Lyerly S; Powell BL
Clin Cancer Res; 2014 Oct; 20(20):5255-64. PubMed ID: 25165100
[TBL] [Abstract][Full Text] [Related]
8. Histone Deacetylase Inhibitors Protect Against Pyruvate Dehydrogenase Dysfunction in Huntington's Disease.
Naia L; Cunha-Oliveira T; Rodrigues J; Rosenstock TR; Oliveira A; Ribeiro M; Carmo C; Oliveira-Sousa SI; Duarte AI; Hayden MR; Rego AC
J Neurosci; 2017 Mar; 37(10):2776-2794. PubMed ID: 28123081
[TBL] [Abstract][Full Text] [Related]
9. Thiamine mimetics sulbutiamine and benfotiamine as a nutraceutical approach to anticancer therapy.
Jonus HC; Byrnes CC; Kim J; Valle ML; Bartlett MG; Said HM; Zastre JA
Biomed Pharmacother; 2020 Jan; 121():109648. PubMed ID: 31810115
[TBL] [Abstract][Full Text] [Related]
10. The Mitochondrial Disruptor Devimistat (CPI-613) Synergizes with Genotoxic Anticancer Drugs in Colorectal Cancer Therapy in a Bim-Dependent Manner.
Arnold C; Demuth P; Seiwert N; Wittmann S; Boengler K; Rasenberger B; Christmann M; Huber M; Brunner T; Linnebacher M; Fahrer J
Mol Cancer Ther; 2022 Jan; 21(1):100-112. PubMed ID: 34750196
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Targeting of the Pyruvate Dehydrogenase Complex/Pyruvate Dehydrogenase Kinase (PDC/PDK) Axis in Cancer.
Stacpoole PW
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059435
[TBL] [Abstract][Full Text] [Related]
12. Formation and anti-tumor activity of uncommon in vitro and in vivo metabolites of CPI-613, a novel anti-tumor compound that selectively alters tumor energy metabolism.
Lee KC; Shorr R; Rodriguez R; Maturo C; Boteju LW; Sheldon A
Drug Metab Lett; 2011 Aug; 5(3):163-82. PubMed ID: 21722089
[TBL] [Abstract][Full Text] [Related]
13. Pyruvate attenuates the anti-neoplastic effect of carnosine independently from oxidative phosphorylation.
Oppermann H; Schnabel L; Meixensberger J; Gaunitz F
Oncotarget; 2016 Dec; 7(52):85848-85860. PubMed ID: 27811375
[TBL] [Abstract][Full Text] [Related]
14. Blockade of glutamine-dependent cell survival augments antitumor efficacy of CPI-613 in head and neck cancer.
Lang L; Wang F; Ding Z; Zhao X; Loveless R; Xie J; Shay C; Qiu P; Ke Y; Saba NF; Teng Y
J Exp Clin Cancer Res; 2021 Dec; 40(1):393. PubMed ID: 34906193
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Mitochondrial Metabolism Leads to Selective Eradication of Cells Adapted to Acidic Microenvironment.
Koncošová M; Vrzáčková N; Křížová I; Tomášová P; Rimpelová S; Dvořák A; Vítek L; Rumlová M; Ruml T; Zelenka J
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639130
[TBL] [Abstract][Full Text] [Related]
16. Src drives the Warburg effect and therapy resistance by inactivating pyruvate dehydrogenase through tyrosine-289 phosphorylation.
Jin Y; Cai Q; Shenoy AK; Lim S; Zhang Y; Charles S; Tarrash M; Fu X; Kamarajugadda S; Trevino JG; Tan M; Lu J
Oncotarget; 2016 May; 7(18):25113-24. PubMed ID: 26848621
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Pyruvate Dehydrogenase Kinase as a Therapeutic Strategy against Cancer.
Sradhanjali S; Reddy MM
Curr Top Med Chem; 2018; 18(6):444-453. PubMed ID: 29788890
[TBL] [Abstract][Full Text] [Related]
18. Multi-Acting Mitochondria-Targeted Platinum(IV) Prodrugs of Kiteplatin with α-Lipoic Acid in the Axial Positions.
Savino S; Marzano C; Gandin V; Hoeschele JD; Natile G; Margiotta N
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30011897
[TBL] [Abstract][Full Text] [Related]
19. Evidence for a novel, effective approach to targeting carcinoma catabolism exploiting the first-in-class, anti-cancer mitochondrial drug, CPI-613.
Guardado Rivas MO; Stuart SD; Thach D; Dahan M; Shorr R; Zachar Z; Bingham PM
PLoS One; 2022; 17(6):e0269620. PubMed ID: 35675354
[TBL] [Abstract][Full Text] [Related]
20. Vitamin C activates pyruvate dehydrogenase (PDH) targeting the mitochondrial tricarboxylic acid (TCA) cycle in hypoxic
Cenigaonandia-Campillo A; Serna-Blasco R; Gómez-Ocabo L; Solanes-Casado S; Baños-Herraiz N; Puerto-Nevado LD; Cañas JA; Aceñero MJ; García-Foncillas J; Aguilera Ó
Theranostics; 2021; 11(8):3595-3606. PubMed ID: 33664850
[No Abstract] [Full Text] [Related]
[Next] [New Search]
